BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

2013 ISPE Facility of the Year Awards Program Names Novartis AG (NVS)'s United States Flu Cell Culture Facility as Overall Winner


11/4/2013 11:21:57 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

(TAMPA, FLA. USA, 04 NOVEMBER 2013) – ISPE announced during the Plenary Session at its 2013 Annual Meeting in Washington, D.C. USA, that Novartis’s United States Flu Cell Culture Facility is the Overall Winner of the 2013 Facility of the Year Awards (FOYA) program.

Novartis’s United States Flu Cell Culture Facility in Holly Springs, North Carolina, USA represents a breakthrough use of innovative technology and development of a large scale manufacturing process to produce seasonal and pandemic influenza vaccines. This innovative process breaks with the 50-year tradition of utilizing eggs for the method of growing the virus in favor of a ground-breaking cell culture technology that offers many potential advantages over the traditional manufacturing process for flu vaccines. These advantages include process raw materials that are readily available and not threatened by pandemic events and closed-system bioreactors that reduce the required biosafety level for the manufacturing space.

The proprietary technology at Novartis’s United States Flu Cell Culture Facility enables flexible and fast start-up of vaccine manufacturing, offering rapid response to potential pandemic influenza threats while fulfilling the need for seasonal influenza vaccines. This project introduces a promising new path for vaccine production, and exemplifies the type of advancements in pharmaceutical and biotechnology manufacturing technology that the FOYA program seeks to recognize. In honor of this accomplishment, Novartis is named the 2013 Facility of the Year Awards Overall Winner More information about Novartis’s winning project, as well as the Facility of the Year Awards program in general, can be found at www.FacilityoftheYear.org.

About the Facility of the Year Awards Program

Sponsored by ISPE, the Facility of the Year Awards (FOYA) program recognizes state-of-the-art pharmaceutical manufacturing projects that utilize new and innovative technologies to enhance the delivery of a quality project, as well as reduce the cost of producing high-quality medicines. Now in its tenth year, the awards program effectively spotlights the accomplishments, shared commitment, and dedication of individuals in companies worldwide to innovate and advance pharmaceutical manufacturing technology for the benefit of all global consumers.

For more information, contact:

DANIELLE HOULD

ISPE Membership Marketing Communications Manager

+1-813-960-2105

dhould@ispe.org

www.ISPE.org

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

ISPE
Novartis AG
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES